• Leveraging cell-penetrating peptides as an alternative to LNPs for safer, more targeted delivery of mRNA payloads
• Enabling extra-hepatic delivery to tissues and cell types beyond the liver, a key limitation of current mRNA therapeutic platforms
• Overcoming endosomal escape and degradation challenges using bio-inspired design and smart vector engineering

NEW COMPANY